|
HIV/HPV Cancer Prevention, Treatment & Pathogenesis: Rwanda/Einstein Consortium
|
5U54CA190163-04
|
$701,778
|
ANASTOS, KATHRYN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Cancer Center Support Grant - UT Southwestern Medical Center
|
3P30CA142543-08S1
|
$175,000
|
ARTEAGA, CARLOS
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
Cancer Center Support Grant - UT Southwestern Medical Center
|
5P30CA142543-08
|
$2,480,000
|
ARTEAGA, CARLOS
|
UT SOUTHWESTERN MEDICAL CENTER
|
|
Cancer Center Support Grant
|
3P30CA082103-18S9
|
$6,765,398
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-18SA
|
$124,999
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA082103-18SB
|
$59,999
|
ASHWORTH, ALAN
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
The GNAQ pathway as a therapeutic target in uveal melanoma
|
5R01CA142873-08
|
$306,698
|
BASTIAN, BORIS
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Cancer Center Support Grant
|
3P30CA042014-28S1
|
$249,799
|
BECKERLE, MARY
|
UNIVERSITY OF UTAH
|
|
Cancer Center Support Grant
|
3P30CA042014-28S2
|
$123,315
|
BECKERLE, MARY
|
UNIVERSITY OF UTAH
|
|
Cancer Center Support Grant
|
3P30CA042014-28S3
|
$46,117
|
BECKERLE, MARY
|
UNIVERSITY OF UTAH
|
|
Cancer Center Support Grant
|
3P30CA042014-28S4
|
$59,999
|
BECKERLE, MARY
|
UNIVERSITY OF UTAH
|
|
Cancer Center Support Grant
|
3P30CA042014-28S5
|
$113,563
|
BECKERLE, MARY
|
UNIVERSITY OF UTAH
|
|
Cancer Center Support Grant
|
3P30CA042014-28S6
|
$75,709
|
BECKERLE, MARY
|
UNIVERSITY OF UTAH
|
|
Cancer Center Support Grant
|
3P30CA042014-28S7
|
$75,000
|
BECKERLE, MARY
|
UNIVERSITY OF UTAH
|
|
Cancer Center Support Grant
|
3P30CA042014-28S8
|
$166,146
|
BECKERLE, MARY
|
UNIVERSITY OF UTAH
|
|
Cancer Center Support Grant
|
5P30CA042014-28
|
$2,284,983
|
BECKERLE, MARY
|
UNIVERSITY OF UTAH
|
|
Stable Water Isotope Labeling for Imaging of Rapidly Proliferating Cells
|
ZIA BC 011777
|
$24,641
|
Buxbaum, Nataliya
|
CCR (NCI)
|
|
Structural Biology of GTPase Activating Proteins
|
ZIA BC 011419
|
$513,634
|
Byrd, R. Andrew
|
CCR (NCI)
|
|
Families at high risk of cancer
|
ZIA CP004410-08285
|
$246,303
|
Caporaso, Neil
|
DCEG (NCI)
|
|
Proteomics of Metastatic and Non-Metastatic Uveal Melanoma
|
1R21CA209500-01A1
|
$206,843
|
CRABB, JOHN
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
Winship Cancer Institute Cancer Center Support Grant
|
2P30CA138292-09
|
$2,524,399
|
CURRAN, WALTER
|
EMORY UNIVERSITY
|
|
Winship Cancer Institute Cancer Center Support Grant
|
3P30CA138292-09S1
|
$59,999
|
CURRAN, WALTER
|
EMORY UNIVERSITY
|
|
Winship Cancer Institute Cancer Center Support Grant
|
3P30CA138292-09S2
|
$102,081
|
CURRAN, WALTER
|
EMORY UNIVERSITY
|
|
Mechanisms of Cross-talk Between EphrinB and Alternate Signaling Pathways
|
ZIA BC 010006
|
$427,953
|
Daar, Ira
|
CCR (NCI)
|
|
Signaling Mechanisms of EphrinB1 in Cell Adhesion, Migration and Invasion
|
ZIA BC 010958
|
$427,953
|
Daar, Ira
|
CCR (NCI)
|
|
Cancer Center Support Grant
|
3P30CA091842-16S1
|
$122,824
|
EBERLEIN, TIMOTHY
|
WASHINGTON UNIVERSITY
|
|
Cancer Center Support Grant
|
3P30CA091842-16S2
|
$243,947
|
EBERLEIN, TIMOTHY
|
WASHINGTON UNIVERSITY
|
|
Cancer Center Support Grant
|
5P30CA091842-16
|
$4,305,712
|
EBERLEIN, TIMOTHY
|
WASHINGTON UNIVERSITY
|
|
Cancer Risk in Myotonic Dystrophy
|
ZIA CP010144-10568
|
$94,531
|
Gadalla, Shahinaz
|
DCEG (NCI)
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-27S1
|
$118,875
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-27S2
|
$60,000
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-27S3
|
$200,000
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-27S4
|
$145,821
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
5P30CA043703-27
|
$4,895,515
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Mechanisms of Action for KCN1 in the Control of Uveal Melanoma Metastasis
|
5R01CA176001-04
|
$323,700
|
GROSSNIKLAUS, HANS
|
EMORY UNIVERSITY
|
|
DEFINING RISK FACTORS FOR NF1-OPTIC GLIOMA
|
5R01CA214146-02
|
$348,844
|
GUTMANN, DAVID
|
WASHINGTON UNIVERSITY
|
|
Molecular Predictive Testing in Ocular Melanoma
|
2R01CA125970-11
|
$561,808
|
HARBOUR, JAMES
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
|
Improving the Clinical Effectiveness and Understanding of the Biophysical Basis
|
5U19CA021239-38
|
$2,457,927
|
HONG, THEODORE
|
MASSACHUSETTS GENERAL HOSPITAL
|
|
Immunotherapy Strategies for Uveal Melanoma
|
ZIA BC 010649
|
$294,260
|
Kammula, Udai
|
CCR (NCI)
|
|
Tumor Microenvironment in Cancer Progression
|
ZIA BC 011332
|
$474,811
|
Kaplan, Rosandra
|
CCR (NCI)
|
|
Translational Research in Cancer
|
3P30CA056036-18S1
|
$58,442
|
KNUDSEN, KAREN
|
THOMAS JEFFERSON UNIVERSITY
|
|
Translational Research in Cancer
|
3P30CA056036-18S2
|
$117,000
|
KNUDSEN, KAREN
|
THOMAS JEFFERSON UNIVERSITY
|
|
Translational Research in Cancer
|
3P30CA056036-18S3
|
$175,000
|
KNUDSEN, KAREN
|
THOMAS JEFFERSON UNIVERSITY
|
|
Translational Research in Cancer
|
5P30CA056036-18
|
$2,807,751
|
KNUDSEN, KAREN
|
THOMAS JEFFERSON UNIVERSITY
|
|
DNA Repair in Human Cancer-Prone Genetic Diseases
|
ZIA BC 004517
|
$1,059,524
|
Kraemer, Kenneth
|
CCR (NCI)
|
|
Clinical Studies of the Molecular Genetic Basis of Kidney Cancer
|
ZIA BC 011028
|
$511,064
|
Linehan, W. Marston
|
CCR (NCI)
|
|
Molecular Therapeutics of Kidney Cancer: VHL Gene and Fumarate Hydratase Gene
|
ZIA BC 011038
|
$1,022,127
|
Linehan, W. Marston
|
CCR (NCI)
|
|
Cancer and Other Mortality Risks in a Cohort of U.S. Radiologic Technologists
|
ZIA CP010133-04180
|
$390,015
|
Linet, Martha
|
DCEG (NCI)
|
|
Specialized Cancer Center Support Grant
|
3P30CA023100-31S1
|
$116,250
|
LIPPMAN, SCOTT
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
|
Specialized Cancer Center Support Grant
|
3P30CA023100-31S2
|
$106,499
|
LIPPMAN, SCOTT
|
UNIVERSITY OF CALIFORNIA SAN DIEGO
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|